Thyroid hormone synthesis and anti-thyroid drugs: a Bioinorganic Chemistry approach by Roy, Gouriprasanna & Mugesh, G.
J. Chem. Sci., Vol. 118, No. 6, November 2006, pp. 619–625. © Indian Academy of Sciences. 
 
 
619 
*For correspondence 
Thyroid hormone synthesis and anti-thyroid drugs: A bioinorganic 
chemistry approach 
GOURIPRASANNA ROY and G MUGESH* 
Department of Inorganic & Physical Chemistry, Indian Institute of Science, Bangalore 560 012 
e-mail: mugesh@ipc.iisc.ernet.in 
Abstract. Hydrogen peroxide, generated by thyroid oxidase enzymes, is a crucial substrate for the thy-
roid peroxidase (TPO)-catalysed biosynthesis of thyroid hormones, thyroxine (T4) and triiodothyronine 
(T3) in the thyroid gland. It is believed that the H2O2 generation is a limiting step in thyroid hormone 
synthesis. Therefore, the control of hydrogen peroxide concentration is one of the possible mechanisms 
for the inhibition of thyroid hormone biosynthesis. The inhibition of thyroid hormone synthesis is re-
quired for the treatment of hyperthyroidism and this can be achieved by one or more anti-thyroid drugs. 
The most widely used anti-thyroid drug methimazole (MMI) inhibits the production of thyroid hormones 
by irreversibly inactivating the enzyme TPO. Our studies show that the replacement of sulphur in MMI 
by selenium leads to a selone, which exists predominantly in its zwitterionic form. In contrast to the sul-
phur drug, the selenium analogue (MSeI) reversibly inhibits the peroxidase-catalysed oxidation and iodi-
nation reactions. Theoretical studies on MSeI reveal that the selenium atom in this compound carries a 
large negative charge. The carbon–selenium bond length in MSeI is found to be close to single-bond 
length. As the selenium atom exhibits a large nucleophilic character, the selenium analogue of MMI may 
scavenge the hydrogen peroxide present in the thyroid cells, which may lead to a reversible inhibition of  
thyroid hormone biosynthesis. 
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1. Introduction 
Thyroxine (T4), the main secretory hormone of the 
thyroid gland, is produced on thyroglobulin by thy-
roid peroxidase (TPO)/hydrogen peroxide/iodide 
system. The synthesis of T4 by TPO involves two 
independent steps: iodination of tyrosine and phenolic 
coupling of the resulting iodotyrosine residues (fig-
ure 1).1 The prohormone T4 is then converted to its 
biologically active form T3 by iodothyronine deio-
dinase (ID-I), which is present in highest amounts in 
liver, kidney, thyroid and pituitary.2 Although the 
deiodination reactions are essential for the function 
of the thyroid gland, the activation of thyroid stimu-
lating hormone (TSH) receptor by auto-antibodies 
leads to an overproduction of thyroid hormones. As 
these antibodies are not under pituitary feedback 
control system, there is no negative influence on the 
thyroid activity and, therefore, the uncontrolled pro-
duction of thyroid hormones leads to a condition 
called “hyperthyroidism” (figure 2). Under these 
conditions, the overproduction of T4 and T3 can be 
controlled by specific inhibitors, which either block 
the thyroid hormone biosynthesis or reduce the con-
version of T4 to T3. A unique class of such inhibi-
tors are the thiourea drugs, methimazole (1, MMI), 
6-n-propyl-2-thiouracil (3, PTU), and 6-methyl-2-
thiouracil (5, MTU) (figure 2). 
 
 
 
 
 
Figure 1. Synthesis of thyroid hormones by heme-
containing thyroid peroxidase (TPO). 
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 Although these compounds are the most commonly 
employed drugs in the treatment of hyperthyroidism, 
the detailed mechanism of their action is still not 
clear. According to the initially proposed mechanism, 
these drugs may divert oxidized iodides away from 
thyroglobulin by forming stable electron donor–
acceptor complexes with diiodine, which can effecti-
vely reduce thyroid hormone biosynthesis.3 It has 
also been proposed that these drugs may block the 
thyroid hormone synthesis by coordinating to the 
metal centre of thyroid peroxidase (TPO).4 After the 
discovery that ID-I is responsible for the activation 
of thyroxine, it has been reported that PTU, but not 
MMI, reacts with the selenenyl iodide intermediate 
(E-SeI) of ID-I to form a selenenyl sulphide as a 
dead end product, thereby blocking the conversion 
of T4 to T3 during the monodeiodination reaction.2 
The mechanism of anti-thyroid activity is further 
complicated by the fact that gold-containing drugs 
such as gold thioglucose (GTG) inhibit the deiodi-
nase activity by reacting with the selenol group of the 
native enzyme.2 
 Recently, the selenium analogues 2 (MSeI), 4 
(PSeU) and 6 (MSeU) attracted considerable atten-
tion.5,6 However, the data derived from the inhibi-
tion of TPO by selenium compounds show that these 
compounds may inhibit the TPO activity by a different 
mechanism. Therefore, further studies are required 
to understand the mechanism by which the selenium 
compounds exert their inhibitory action. Our initial 
attempts to isolate 2 were unsuccessful and the final 
stable compound in the synthesis was characterized 
to be the diselenide (8). In view of the current inter-
est in anti-thyroid drugs and their mechanism, we  
 
 
 
 
 
Figure 2. Pituitary feedback control system and anti-
thyroid drugs. 
extended our approach to the synthesis and biologi-
cal activities of a number of sulphur and selenium 
derivatives bearing the methimazole pharmacophore.6 
In this paper, we discuss our experimental evidences 
that replacement of the sulphur atom in methimazole 
by selenium leads to a completely different mecha-
nism. In addition, we describe the effect of a range 
of sulphur and selenium compounds bearing the me-
thimazole moiety on peroxidase-catalysed oxidation 
reactions. We also describe the effect of substituents 
attached to the imidazole moiety on the selenol-
selone tautomerism by theoretical calculations.  
2. Results and discussion 
The tautomeric behaviour of MMI has been sub-
jected to many investigations,7 which show that 
MMI exists almost exclusively as the thione tauto-
mer (1a). Recent studies have shown that the thio-
urea-based drugs PTU and MTU also exist as thione 
tautomers.8 The stability of the thione tautomers 
may prevent these compounds from being oxidized 
to their corresponding disulphides, which may ac-
count for their high anti-thyroidal activity. Laurence 
et al have shown that the thione tautomer of MMI is 
responsible for its complexation with diiodine and 
the iodine complex of the thione tautomer 1a is fa-
voured by 13⋅2 kJ mol–1 compared to that of the 
thiol tautomer 1b.9a Therefore, the facile oxidation 
of 2 to the corresponding diselenide (8) requires the 
compound to be in its zwitterionic form (2c) and not 
in the true selone form (2a). Although compound 2 
can exist in both selenol and selone forms in solu-
tion, the 77Se NMR spectrum recorded immediately 
after the workup of the reaction showed a signal at  
–5 ppm, which can be ascribed to the zwitterionic 
(2c) tautomer (figure 3). In the presence of air, the 
zwitterion slowly oxidizes to the corresponding 
diselenide and this process continues until all  
the zwitterion is converted to diselenide 8. In 
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E
H NHN Me
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(1a) E = S
 
 
Figure 3. Proposed tautomeric structures of MMI and 
MSeI. 
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contrast, the sulphur analogue, which exists pre-
dominantly in its thione tautomer form (1a), was 
found to very stable and could not beginning con-
verted to the corresponding disulfide (7) even by us-
ing oxidizing agents such as O2, H2O2 etc. It should 
be mentioned that MMI is readily oxidized by the 
TPO system to form the disulfide. Although the oxi-
dation of this compound by iodine has been postu-
lated to be a possible mechanism,10 the chemical 
way through which MMI is transformed into disul-
fide 6 in vivo is unknown.  
 The theoretical investigations on selones are 
highly limited to the compounds having simple sub-
stituents, mainly due to the requirement of large ba-
sis sets for the calculations.11 The relatively larger 
size and greater polarizability of selenium as com-
pared with sulphur have led to the assumption that 
the compounds with selone moiety are less stable 
than their sulphur analogues. Because the inhibition 
of TPO by antithyroid drugs depends upon the redox 
state of sulphur or selenium, we performed detailed 
quantum chemical calculations on 1 and 2 in gas 
phase. These studies show that the formation of the 
diselenide (8) from 2c is energetically more favoured 
than the formation of the disulfide (7) from the cor-
responding thiol (1b). Interestingly, the conversion 
of thiol to thione is more favoured than the conver-
sion of selenol to the corresponding selone. This can 
be rationalized by comparing the relative position of 
hydrogen on sulphur or selenium with respect to N1 
in their most stable conformations. In the selenol 
(2b, figure 4), the H atom is located away from N1 
leading to an increase in the energy barrier for the 
selenol–selone conversion. In contrast, the H atom is 
located in the close proximity of N1 in the thiol (1b, 
figure 2), which may favour the thiol-thione conver-
sion. As the thione form is calculated to be much 
more stable than the corresponding thiol, it is quite 
unlikely that the thiol form contributes to the anti-
thyroid activity of MMI. However, when the calcu-
lations were performed by including solvent effects, 
compound 2 was found to exist only in the zwitteri-
onic form. Although the selone (2a) was also calcu-
lated to be more stable than the selenol (2b), the 
facile oxidation of the zwitterion to the corresponding 
diselenide disfavours the existence of selenol tauto-
mer. 
 Although compound 2 readily oxidizes to dise-
lenide 8, the corresponding zwitterion (2c) can be 
conveniently obtained by reducing the diselenide by 
NaBH4 or glutathione (GSH). The reaction of 8 with 
NaBH4 followed by aqueous workup afforded the 
zwitterion as white solid, which was found to be 
stable under inert atmosphere and could be employed 
for in vitro biological assays without any noticeable 
oxidation. The treatment of diselenide 8 with 2 
equiv. of GSH has also produced the zwitterion in 
nearly quantitative yield. Interestingly, the forma-
tion of a true selone (2a) was not observed in any of 
these processes, supporting the theoretical calcula-
tions that the selone exists as the zwitterion (2c) due 
to the nitrogen atoms present in the imidazole ring. 
The 1H and 13C NMR data and the large upfield shift 
in the 77Se NMR chemical shift for the zwitterion  
(–5 ppm), supports this assumption. In agreement 
with the theoretical data, the 77Se NMR experiments 
show that the selone is more dissociated in water  
(–53 ppm) than in organic solvent (–5 ppm) as evi-
denced by a large upfield shift when changing the 
solvent from CDCl3 to D2O. The facile reduction of 
8 by GSH suggests that this compound may exist in 
its zwitterionic form under in vivo conditions, be-
cause GSH is present in the thyroid gland in high 
concentrations. It has been shown that GSH is an 
important antioxidant in thyroid gland and the per-
oxide scavenging activity of MMI is considerably 
increased by GSH.12 
 The enzyme inhibition experiments were carried 
out with Fe-containing lactoperoxidase (LPO) since 
it is readily available in purified form. Furthermore, 
LPO has been shown to behave very similarly to TPO 
with respect to iodination of thyroglobulin, the natu-
ral substrate, and other iodide acceptors.13 Edelhock 
et al have reported the inactivation of LPO by thio-
urea-based drugs using LPO-N-acetyltyrosylamide 
assay.14 We have employed 2,2′-azio-bis 3-ethyl-
benthiazoline-6-sulphonic acid (ABTS) and H2O2 as 
substrates to determine the half-maximal inhibitory 
concentration (IC50) of test compounds. The IC50 
values for the inhibition of LPO-catalysed oxidation 
of ABTS by 1–3 and 5 are summarized in table 2.  
 To obtain reliable IC50 values for compound 2 and 
to make a direct comparison with the sulphur ana-
logue, it is important to carry out the inhibition ex-
periments with the completely reduced species. 
Therefore, we carried out the experiment with the 
reduced species (zwitterion, 2c), which was obtained 
by reducing the diselenide (8) with NaBH4 in an 
aqueous solution. As expected, MMI inhibited the 
LPO activity with an IC50 value of 7⋅8 µM, which is 
much lower than that observed with PTU and MTU. 
The selenium analogue (2c) also inhibited LPO, and 
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Figure 4. Optimized geometries of 1 and 2. The conversion of thiol to thione is more favoured than the conversion of 
selenol to selone. The structures were optimised at the B3LYP level of theory using 6-311++G (d, p) basis set. 
 
 
Table 1. The theoretical data for 2 and 8 obtained by 
DFT calculations at B3LYP/6-311++G (d, p) level along 
with the GIAO 77Se NMR chemical shifts. 
 C–Se bond  77Se Chemical 
Compound  length (Å) shift (ppm)b 
 
2a 1⋅835  30 
2b 1⋅917 –101 
2c 1⋅835  30 
8  1⋅902a 386 
aCalculated using B3LYP/6-31G(d) level; bNMR values 
were calculated using B3LYP/6-311++G(2d,p) level and 
referenced to Me2Se 
 
Table 2. Inhibition of LPO activity by 1–3, and 5. 
Compound IC50 (µM)a 
 
MMI (1)  7⋅0 ± 1⋅1 
MSeI
 
(2) 16⋅4 ± 1⋅5 
PTU (3) 45⋅0 ± 2⋅1 
MTU (5) 47⋅8 ± 0⋅1 
aConcentration of the compound causing 50% inhibition. 
Each IC50 value was calculated from at least three inde-
pendent experiments 
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Figure 5. A hypothetical model for the coordination of 
thiourea drugs to the Fe-centre of TPO. 
 
the IC50 value was found to be almost 4–5 times 
lower than that of PTU and MTU. The higher acti-
vity of MMI as compared with PTU and MTU is in 
agreement with the previous studies on the inhibi-
tion of TPO. Since the activation of the iron centre in 
TPO must proceed through an interaction of Fe(III) 
with H2O2, TPO inactivation may occur through a 
competitive coordination of the drug to iron, assisted 
by hydrogen bonding with a histidine residue of the 
TPO enzyme (figure 5). Under these conditions, 
MMI might compete more successfully than PTU 
with H2O2, because the hydrogen-bond (hard) ba-
sicity pkHB value of MMI (2⋅11) is much higher than 
that of PTU (~ 1⋅32). Similar to PTU, the methyl de-
rivative 5 is also expected to be a weak inhibitor of 
TPO. On the other hand, compound 2, which exists 
predominantly in its zwitterionic form, does not 
have the ability to coordinate to the iron centre and, 
therefore, this compound must inhibit the LPO 
activity by a different mechanism. 
 Taurog et al have shown that MMI and related de-
rivatives irreversibly inhibit LPO and TPO, leading 
to a complete inactivation of the enzymes.15 Doerge 
and others have shown that mammalian peroxidases 
including LPO may activate the anti-thyroid drugs 
through S-oxygenation to produce the corresponding 
sulphoxides or sulphenic acids.16 They have also 
shown that the irreversible inactivation of LPO and 
TPO by MMI proceeds through the S-oxygenation 
of the thione moiety to form a reactive sulphenic 
acid, which binds covalently to the prosthetic heme 
and irreversibly blocks enzyme activity.17 Given the 
higher reactivity of selenium compounds as compared 
with the sulphur derivatives towards oxidation, it is 
possible that the facile oxidation of the selenium 
compounds may lead to an efficient inhibition of 
LPO activity. With this in mind, we treated all the 
compounds in this study with H2O2 before adding 
LPO and ABTS. The LPO activity was measured 
several times by increasing the time for the reaction 
of the test compounds with H2O2. Remarkably, 
MSeI (2) inhibited the enzyme within few seconds 
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even at lower concentrations, which can be ascribed 
to the facile oxidation of the reactive selenium moi-
ety in 2 (MSeI) by H2O2. Because MMI also inhibits 
the enzyme very efficiently, we have carried out fur-
ther experiments to prove that the mechanisms by 
which MMI and MSeI exert their inhibitory action 
are different. The initial rates (vo) derived from vari-
ous concentrations of H2O2 were plotted against the 
concentration of H2O2. The LPO activity was com-
pletely inhibited by 40 µM MMI and the enzyme’s 
activity could not be recovered by increasing the 
H2O2 concentration (figure 6, d). The LPO activity 
could not be recovered even at lower concentration 
of MMI (10 µM) and higher concentration of H2O2 
(230 µM). This suggests that MMI does not act on 
H2O2, but it acts on the enzyme itself leading to an 
irreversible inhibition as previously proposed. On 
the other hand, 2 also inhibited the LPO activity as 
efficient as MMI, but in this case, the enzyme’s ac-
tivity could be completely recovered by increasing 
H2O2 concentration (figure 6, b). The sigmoidal be-
haviour of the graph for this compound (figure 6, b) 
is probably due to the utilization of H2O2 for the 
oxidation of selenenic acid to other oxidized prod-
ucts at lower concentration of the peroxide. 
 These observations strongly support the assump-
tion that MSeI, in contrast to MMI, does not inter-
fere with the enzyme directly, but it inhibits the LPO  
 
 
 
 
 
Figure 6. Plot of initial rates (vo) for the LPO-catalysed 
oxidation of ABTS vs concentration of H2O2. (a) Control 
activity, (b) 40 µM of 2, (c) 40 µM of 8, (d) 80 µM of 
PTU, (e) 80 µM of MTU, (f) 40 µM of MMI. Condi-
tions: LPO: 6⋅5 nM; H2O2: 22⋅9 µM. 
activity by reducing the H2O2, which is required for 
the oxidation of the iron centre in LPO (figure 7). 
When coupled with a suitable thiol such as GSH, 
compound 2 may constitute redox cycle involving a 
catalytic reduction of H2O2 (glutathione peroxidase 
(GPx) activity).18 In this way, compound 2 mimics 
the action of GPx, a selenoenzyme that protects the 
cellular components from oxidative damage by re-
ducing H2O2 with the help of GSH. Recently, the 
GPx enzyme present in thyroid gland has been 
shown to inhibit the iodination reactions by degrad-
ing the intracellular H2O2.19 In fact, the key com-
pound 2 exhibited interesting GPx activity, leading 
to an assumption that some of the antithyroid drugs 
may act as antioxidants in addition to their inhibi-
tion behaviour. However, GSH does not appear to be 
a suitable thiol co-substrate for the catalytic antioxi-
dant activity of 2, because the reaction of 2 with hy-
drogen peroxide was found to be much faster than 
the reduction of the intermediate selenenic acid 
and/or other oxidized species by GSH. Similar to the 
zwitterion-mediated inhibition, the inhibition by 
diselenide 8 could also be reversed by increasing the 
H2O2 concentration (figure 6, c). Although com-
pound 8 did not give any new 77Se NMR signal with 
one equiv. H2O2, addition of an excess amount of 
H2O2 to 8 produced a new signal at 1045 ppm, 
which cannot be ascribed to the selenenic acid be-
cause this signal appears to be different from that 
obtained from the reaction of 2 with H2O2, which 
showed a signal at 1207 ppm. 
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Figure 7. A hypothetical model representing the inhibi-
tion of LPO by 2. The porphyrin core inside the circle 
represents the active centre of LPO. AA: amino acid resi-
dues.  
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 As expected, the plot of initial rates (vo) vs con-
centration of MSeI shows that the rate of the reaction 
decreases with increasing concentration of MSeI. In 
all these cases, the LPO activity could be recovered 
by increasing the hydrogen peroxide concentration. 
These experimental observations support the conclu-
sions made by Taurog et al that MSeI, unlike MMI, 
cannot act as an irreversible inhibitor of TPO. These 
observations also support the in vivo experiments, 
which showed that MMI is at least 50 times more 
potent than MSeI as an inhibitor of organic iodine 
formation in the thyroid. Crucially, the treatment of 
2 with the selenolate specific reagent, iodoacetic 
acid, abolished the inhibitory potency of 2, confirm-
ing that the oxidation of the selenium centre by 
H2O2 is responsible for the inhibition. In contrast, 
the sulphur analogue MMI was found to be less sen-
sitive to the iodoacetic acid treatment and this also 
confirms that the thiol form of MMI is not only less 
predominant in solution, but also less reactive as 
compared with the thione form.  
3. Conclusion 
In summary, our experimental and theoretical stud-
ies show that the selenium analogue of methimazole 
(MSeI) exists predominantly in its zwitterionic form 
whereas the sulphur compound exists in its thione 
form and the oxidation of the zwitterion to the cor-
responding diselenide is energetically more favoured 
than the conversion of thione/thiol to the corre-
sponding disulfide. Although MSeI readily oxidizes 
to produce the diselenide, the oxidized form can be 
easily reduced by reducing agents such as NaBH4 or 
glutathione (GSH). The 77Se NMR studies show that 
the selone form of MSeI dissociates in solution to 
form a more reactive selenolate, which could be 
trapped by selenolate specific reagents such as iodo-
acetic acid. In its reduced form, MSeI effectively 
and reversibly inhibits the iron-containing lactoper-
oxidase (LPO). In contrast to methimazole, MSeI 
does not interfere with the enzyme directly, but it 
inhibits LPO by reducing the H2O2 that is required 
for the oxidation of the iron centre in LPO. In the 
presence of GSH, MSeI constitutes a redox cycle in-
volving a catalytic reduction of H2O2 and thereby 
mimics the glutathione peroxidase (GPx) activity in 
vitro. These studies reveal that the degradation of 
the intracellular H2O2 by the selenium analogues of 
anti-thyroid drugs may be beneficial to the thyroid 
gland as these compounds may act as antioxidants 
and protect thyroid cells from oxidative damage. 
Because the drugs with an action essentially on 
H2O2 can reversibly inhibit the thyroid peroxidase, 
such drugs with a more controlled action could be of 
great importance in the treatment of hyperthyroidism. 
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